NASDAQ: OLMA - Olema Pharmaceuticals, Inc.

Yield per half year: -61.96%
Sector: Healthcare

Share chart Olema Pharmaceuticals, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About

Olema Pharmaceuticals, Inc., биофармацевтическая компания, работающая на клинической стадии, занимается открытием, разработкой и коммерциализацией методов лечения рака у женщин. Его ведущей программой является OP-1250, антагонист рецептора эстрогена (ER) и селективный деградиатор ER, который находится в фазе 1/2 клинических испытаний для лечения метастатического или местнораспространенного, ER-положительного и рецептора 2 эпидермального фактора роста человека. -отрицательный рак груди. Компания была ранее известна как CombiThera, Inc. и сменила название на Olema Pharmaceuticals, Inc.

more details
в марте 2009 года. Olema Pharmaceuticals, Inc. была зарегистрирована в 2006 году, ее штаб-квартира находится в Сан-Франциско, Калифорния.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2020-11-19
ISIN US68062P1066
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Див.доход ао 0
Сайт https://www.olema.com
Цена ао 5.04
Change price per day: +1.71% (5.85)
Change price per week: +5.12% (5.66)
Change price per month: -5.85% (6.32)
Change price per 3 month: -48.48% (11.55)
Change price per half year: -61.96% (15.64)
Change price per year: -46.68% (11.16)
Change price per 3 year: +32.22% (4.5)
Change price per 5 year: 0% (5.95)
Change price per 10 year: 0% (5.95)
Change price per year to date: -3.25% (6.15)
All parameters

Underestimation

Title Value Grade
P/S 0 0
P/BV 2.6 6
P/E 0 0
EV/EBITDA -5.68 0
Total: 3.13

Efficiency

Title Value Grade
ROA, % -34.9 0
ROE, % -38.07 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.0231 10
Total: 9.2

Growth impulse

Title Value Grade
Yield Revenue, % 0 0
Yield Ebitda, % 2332.19 10
Yield EPS, % 599 10
Total: 8
More

Institutions Volume Share, %
BVF Inc. 9135893 16.34
Paradigm Biocapital Advisors LP 7903600 14.14
Logos Global Management LP 4383875 7.84
Blackrock Inc. 3263907 5.84
Vanguard Group Inc 2705895 4.84
Cormorant Asset Management, LP 2456800 4.39
Deep Track Capital, LP 1930894 3.45
Vivo Capital, LLC 1873704 3.35
MPM BioImpact Capital LLC 1857136 3.32
Dimensional Fund Advisors LP 1715420 3.07

ETF Share, % Profitability for 1 year, % Dividends, %
Virtus LifeSci Biotech Clinical Trials ETF 0.86661 63.04 0.33
iShares Micro-Cap ETF 0.13817 17.09 1.54048
Direxion Daily S&P Biotech Bull 3x Shares 0.11012 4067.92 0.25924
Future Tech ETF 0.07401 426.34 0.8416
Principal Healthcare Innovators ETF 0.07401 618.5 0.8416
Invesco Nasdaq Biotechnology ETF 0.07319 28.58 0.8565
Vanguard U.S. Momentum Factor ETF 0.06 30.05 1.05834
ProShares Ultra Nasdaq Biotechnology 0.04759 51.7 0.85651
Avantis U.S Small Cap Equity ETF 0.02117 27.77 1.68271
Vanguard Russell 2000 ETF 0.02 17.16 1.48801
iShares Morningstar Small Cap Value ETF 0.01629 26.7 2.50476
iShares Morningstar Small-Cap Value ETF 0.01629 201.65 2.50476
ProShares UltraPro Russell2000 0.01177 89.82 1.47873
iShares Russell 2000 Growth ETF 0.01043 38.04 0.6026
Vanguard Russell 2000 Growth ETF 0.01 23.05 0.60264
iShares Morningstar Small-Cap ETF 0.0078 30.1 1.60498
iShares Morningstar Small-Cap ETF 0.0078 391.25 1.60498
Fidelity MSCI Health Care Index ETF 0.00587 3 1.46057
Dimensional U.S. Core Equity 2 ETF 0.0054 30.76 1.47098
ProShares Hedge Replication ETF 0.00312 5.92 1.47892
Humankind US Stock ETF 0.00293 18.81 1.99919
Avantis U.S. Equity ETF 0.00158 23.04 1.59151
Dimensional US Core Equity Market ETF 0.00152 30.98 1.40618
SPDR Portfolio MSCI Global Stock Market ETF 0.0013 17.99 2.19607
iShares Russell 3000 ETF 0.00109 24.83 1.43482
Dimensional U.S. Equity ETF 0.00061 31.53 1.3557
Vanguard Russell 3000 ETF 0 31.87 1.43817



Head Job title Payment Year of birth
Mr. Shane William Charles Kovacs M.B.A. Chief Operating & Financial Officer 726.17k 1974 (51 year)
Ms. Julie Dexter Senior VP & Head of People N/A
Dr. Sean P. Bohen M.D., Ph.D. President, CEO & Director 1M 1967 (58 years)
Dr. David C. Myles Ph.D. Chief Discovery & Non-Clinical Development Officer 200k 1963 (62 years)
Ms. Demiana Faltaos Ph.D., Pharm.D. VP & Head of Clinical Pharmacology N/A
Dr. Naseem Zojwalla M.D. Chief Medical Officer 775.48k 1973 (52 years)
Ms. Sasha Austin CPA VP of Finance & Controller N/A
Mr. John B. Moriarty Jr., ESQ., J.D. Corporate Secretary 1968 (57 years)

Address: United States, San Francisco, CA , 512 2nd Street - open in Google maps, open in Yandex maps
Website: https://www.olema.com